BRIDGEWATER, N.J.--(BUSINESS WIRE)--April 3, 2006--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN - News) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of an Investigational New Drug (IND) application for the use of Enzon’s oncology product, ONCASPAR® (pegaspargase) in the treatment Non-Hodgkin’s Lymphoma and certain solid tumors. ONCASPAR is currently approved for patients with acute lymphoblastic leukemia (ALL) who require L-asparaginase in their treatment but have developed hypersensitivity to the native forms of L-asparaginase. Pre-clinical studies suggest ONCASPAR may also have activity in other cancers.
